

## INCIDENCE RATE OF HEPATITIS C VIRUS INFECTION IN THE PRISON SETTING: THE STOP-C STUDY

### Authors:

Hajarizadeh B<sup>1</sup>, Carson JM<sup>1</sup>, Byrne M<sup>1</sup>, Grebely J<sup>1</sup>, Cunningham E<sup>1</sup>, Amin J<sup>2</sup>, Vickerman P<sup>3</sup>, Martin NK<sup>4</sup>, Treloar C<sup>5</sup>, Martinello M<sup>1</sup>, Lloyd AR<sup>1</sup>, Dore GJ<sup>1</sup> on behalf of the SToP-C study group

<sup>1</sup>. The Kirby Institute, UNSW, Sydney, Australia, <sup>2</sup>. Faculty of Medicine and Health Sciences, Macquarie University, Sydney, Australia, <sup>3</sup>. Population Health Sciences, University of Bristol, Bristol, UK, <sup>4</sup>. Division of Infectious Diseases & Global Public Health, University of California San Diego, San Diego, USA, <sup>5</sup>. Centre for Social Research in Health, UNSW, Sydney, Australia

### Background:

People in prison are at greater risk of HCV infection given high prevalence of injecting drug use and limited access to harm reduction services. This study evaluated HCV incidence and associated injecting drug use characteristics in prisons.

### Methods:

The SToP-C study enrolled people incarcerated in four Australian prisons. At enrolment, participants were tested for anti-HCV and HCV RNA (if anti-HCV positive). Participants at-risk of HCV primary infection (anti-HCV negative) or re-infection (anti-HCV positive, HCV RNA negative) were eligible for this analysis. Participants were tested for HCV every 3-6 months (October-2014 to November-2019).

### Results:

Among 3,691 participants, 1,643 were at-risk of HCV, had at least one follow-up visit, and were included in analyses (82% male; median age: 33 years; 30% reported injecting drugs during current imprisonment). During 1,818 person-years follow-up, HCV incidence was 6.1/100 person-years (95%CI: 5.1-7.4), with higher incidence of re-infection (9.3/100 person-years; 95%CI: 7.2-12.2) than primary infection (4.6/100 person-years; 95%CI: 3.6-6.0). HCV incidence was highest among participants who injected drugs during current imprisonment (15.1/100 person-years, 95%CI: 12.1-18.8; Figure). Among participants injecting drugs in the past month (n=321), a decreased risk of HCV was associated with receiving high-dosage opioid agonist therapy (OAT, i.e., methadone:  $\geq 60$  mg/day; buprenorphine:  $\geq 16$  mg/day) [versus no OAT, adjusted hazard ratio (aHR): 0.11, 95%CI: 0.02-0.80], and older age (per year, aHR: 0.95, 95%CI: 0.91-0.99). Compared with participants not using any shared needles/syringes, risk of HCV was significantly higher among those who shared needles/syringes without consistent use of disinfectant to clean equipment (aHR: 4.60, 95%CI: 1.35-15.66), while the risk was higher but not statistically significant among those who shared needles/syringes and consistently used disinfectant (aHR: 2.15, 95%CI: 0.81-5.74).

### Conclusion:

HCV transmission risk is high in prison, particularly among those reporting ongoing injecting drugs. HCV prevention strategies should ensure access to high-dosage OAT, and sterile injecting equipment.

### Disclosure of Interest Statement:

The Kirby Institute is funded by the Australian Government Department of Health and Ageing. The SToP-C study is a partnership project involving the Kirby Institute, Justice Health and Forensic Mental Health Network, Corrective Services NSW, NSW Ministry of Health, NSW Users and AIDS Association, Hepatitis NSW, and Gilead Sciences. The SToP-C study group includes members of the Protocol Steering Committee; Coordinating Centre, The Kirby Institute, UNSW; and Study Site Co-ordinators. The views expressed in this publication are those of the authors and do not necessarily represent the position of the Australian Government or Gilead Sciences.




Figure: Cumulative incidence of HCV infection among participants, by injecting drug use status at the beginning of the follow-up